A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate

British Journal of Anaesthesia

Volumn 83, Issue 3, 1999, Pages 397-404

  Nakane, M ^a   Iwama, H ^a  

^a Central Aizu General Hospital   (Japan)

Author keywords

Anaesthetics i.v., propofol; Anaesthetics local, lidocaine; Pain, injection; Pharmacology, nafamostat

Indexed keywords

BRADYKININ; INTRAVENOUS ANESTHETIC AGENT; KALLIKREIN INHIBITOR; LIDOCAINE; NAFAMSTAT MESILATE; PROPOFOL; SOLVENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; KALLIKREIN KININ SYSTEM; MAJOR CLINICAL STUDY; MALE; NERVE ENDING; PERIPHERAL VEIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032826937     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/83.3.397     Document Type: Article

References (32)

1. Scott RPF, Saunders DA, Norman J. Propofol: clinical strategies for preventing the pain of injection. Anaesthesia 1988; 43: 492-4
2. Gehan G, Karoubi P, Quinet F, Leroy A, Rathat C, Pourriat JL. Optimal dose of lignocaine for preventing pain on injection of propofol. Br J Anaesth 1991; 66: 324-6
3. King SY, Davis FM, Wells JE, Murchison DJ, Pryor BJ. Lidocaine for the prevention of pain due to injection of propofol. Anesth Analg 1992; 74: 246-9
4. Eriksson M, Englesson S, Niklasson F, Hartvig P. Effects of lignocaine and pH on propofol-induced pain. Br J Anaesth 1997; 78: 502-6
5. Iwama H, Nakane M, Ohmori S, et al. Nafamostat mesilate, a kallikrein inhibitor, prevents pain on injection with propofol. Br J Anaesth 1998; 81: 963-4
6. Fujii S, Hitomi Y. New synthetic inhibitors of Clr, Cl esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981; 661: 342-5
7. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985; 15: 164-8
8. Paque EC, Römisch J. Comparative study on the in vitro effectiveness of antithrombotic agents. Thromb Res 1991; 64: 11-21
9. Marunaka T, Maniwa M, Matsushima E, et al. High-performance liquid chromatographic determination of 6-amidino-2-naphthyl [4-(4,5-dihydro-1H-imidazol-2yl) amino] benzoate dimethanesulphonate and its metabolites in biological fluids. J Chromatogr 1988; 433: 177-86
10. Ando T, Shimamoto K, Nakahashi Y, et al. Blood kinin measurement by sensitive kinin radioimmunoassay and its clinical application. In: Fritz H, Dietze G, Fiedler F, Haberland GL, eds. Recent Progress on Kinins, International Conference Kinin 81 Munich. Basel, Boston, Stuttgart: Birkhäuser Verlag, 1982; 222-6
11. Okajima K, Uchiba M, Murakami K. Nafamostat mesilate. Cardiovasc Drug Rev 1995; 13: 51-65
12. Koshiyama Y, Ozeki M, Motoyoshi A, Fujita M, Iwaki M, Aoyama T. Pharmacological studies of FUT-175, nafamstat mesilate: effects on coagulation, platelets and fibrinolysis. Folia Pharmacol Japon 1984; 84: 417-28
13. Aoyama T. Nafamstat mesilate. Drugs of the Future 1984; 9: 747-8
14. Urabe Y, Ideishi M, Sasaguri M, Ikeda M, Arakawa K. Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol 1993; 72: 218-22
15. Okamoto T, Mizoguchi S, Terasaki H, Morioka T. Safety of high-dose of nafamostat mesilate: Toxicological study in beagles. J Pharmacol Exp Ther 1994; 268: 639-44
16. Maruyama H, Miyakawa Y, Gejyo F, Arakawa M. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient. Nephron 1996; 74: 468-9
17. Nanpo T, Ohtsuki T, Jin Y, et al. Pharmacokinetic studies of FUT-175 (nafamstat mesilate) (I): blood level profiles, tissue distribution, metabolism and excretion in rats after intravenous administration. KISO TO RINSHO 1984; 18: 3971-92
18. Proud D, Kaplan AP. Kinin formation: mechanisms and role of inflammatory disorders. Annu Rev Immunol 1988; 6: 49-83
19. Takahashi TA, Abe H, Fujihara M, et al. Quality of platelet components: the role of suspension medium and leukocyte depletion. Transfus Clin Biol 1994; 6: 481-7
20. Takahashi TA, Abe H, Hosoda M, Nakai K, Sekiguchi S. Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter. Transfusion 1995; 35: 967
21. Sano H, Koga Y, Hamasaki K, Furuyama H, Itami N. Anaphylaxis associated with white-cell reduction filter. Lancet 1996; 347: 1053
22. Dray A, Patel IA, Perkins MN, Rueff A. Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro. Br J Pharmacol 1992; 107: 1129-34
23. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci 1993; 16: 99-103
24. Bönner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 (Suppl. 6): S46-56
25. Klement W, Arndt JO. Pain on injection of propofol: Effects of concentration and diluent. Br J Anaesth 1991; 67: 281-4
26. Dewandre J, Van Bos R, Van Hemelrijck J, Van Aken H. A comparison of the 2% and 1% formulations of propofol during anaesthesia for craniotomy. Anaesthesia 1994; 49: 8-12
27. Servin FS, Desmonts JM, Melloni C, Martinelli G. A comparison of 2% and 1% formulations of propofol for the induction and maintenance of anaesthesia in surgery of moderate duration. Anaesthesia 1997; 52: 1216-21
28. Doenicke AW, Roizen MF, Rau J, Kellermann W, Babl J. Reducing pain during propofol injection: The role of the solvent. Anesth Analg 1996; 82: 472-4
29. McCrirrick A, Hunter S. Pain on injection of propofol: the effect of injectate temperature. Anaesthesia 1990; 45: 443-4
30. Barker P, Langton JA, Murphy P, Rowbotham DJ. Effect of prior administration of cold saline on pain during propofol injection: a comparison with cold propofol and propofol with lignocaine. Anaesthesia 1991; 46: 1069-70
31. Jadoul M, Struyven J, Stragier A, et al. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1991; 337: 112-13
32. Fried MR, Eastlund T, Christie B, Mullin GT, Key NS. Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotension-converting enzyme inhibitor therapy. Transfusion 1996; 36: 900-3